JP2015508411A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508411A5 JP2015508411A5 JP2014551726A JP2014551726A JP2015508411A5 JP 2015508411 A5 JP2015508411 A5 JP 2015508411A5 JP 2014551726 A JP2014551726 A JP 2014551726A JP 2014551726 A JP2014551726 A JP 2014551726A JP 2015508411 A5 JP2015508411 A5 JP 2015508411A5
- Authority
- JP
- Japan
- Prior art keywords
- layer
- optionally
- subcoating
- nucleus
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000010410 layer Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000009498 subcoating Methods 0.000 claims description 5
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000011247 coating layer Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 2
- 229960003089 pramipexole Drugs 0.000 claims description 2
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims description 2
- 229960000245 rasagiline Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261585824P | 2012-01-12 | 2012-01-12 | |
| US61/585,824 | 2012-01-12 | ||
| PCT/IL2013/050025 WO2013105092A1 (en) | 2012-01-12 | 2013-01-10 | Fixed dose combination therapy of parkinson's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508411A JP2015508411A (ja) | 2015-03-19 |
| JP2015508411A5 true JP2015508411A5 (enExample) | 2017-05-18 |
| JP6243351B2 JP6243351B2 (ja) | 2017-12-06 |
Family
ID=48781101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551726A Active JP6243351B2 (ja) | 2012-01-12 | 2013-01-10 | パーキンソン病の固定投与量薬剤組合せ治療 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20150079187A1 (enExample) |
| EP (1) | EP2802319B1 (enExample) |
| JP (1) | JP6243351B2 (enExample) |
| KR (2) | KR102276896B1 (enExample) |
| CN (1) | CN104168896B (enExample) |
| AU (1) | AU2013208653B2 (enExample) |
| CA (1) | CA2860952C (enExample) |
| CY (1) | CY1119793T1 (enExample) |
| DK (1) | DK2802319T3 (enExample) |
| ES (1) | ES2655676T3 (enExample) |
| HU (1) | HUE038029T2 (enExample) |
| IL (1) | IL233572B (enExample) |
| IN (1) | IN2014MN01568A (enExample) |
| LT (1) | LT2802319T (enExample) |
| MX (1) | MX360409B (enExample) |
| NO (2) | NO2802319T3 (enExample) |
| PL (1) | PL2802319T3 (enExample) |
| PT (1) | PT2802319T (enExample) |
| RS (1) | RS56742B1 (enExample) |
| RU (1) | RU2642962C9 (enExample) |
| WO (1) | WO2013105092A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2007369A4 (en) | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| CN104367565A (zh) * | 2014-11-21 | 2015-02-25 | 哈尔滨圣吉药业股份有限公司 | 一种盐酸普拉克索缓释微丸 |
| CN105147627B (zh) * | 2015-08-19 | 2019-04-12 | 天津红日药业股份有限公司 | 一种含有盐酸普拉克索的药物组合物及其制备方法 |
| CA3072994A1 (en) * | 2017-08-17 | 2019-02-21 | Zi-Qiang Gu | Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof |
| CA3122935A1 (en) * | 2018-12-19 | 2020-06-25 | Galecto Biotech Ab | Amorphous form and process |
| WO2021109880A1 (zh) * | 2019-12-06 | 2021-06-10 | 上海医药集团股份有限公司 | 药物组合物、成套药盒及其应用 |
| WO2023112024A1 (en) * | 2021-12-14 | 2023-06-22 | Pharma Two B Ltd. | Method of treating parkinson's disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL215263B1 (pl) * | 2002-02-25 | 2013-11-29 | Elan Pharm Inc | Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku |
| WO2005070428A1 (en) * | 2004-01-22 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist |
| KR20060124712A (ko) * | 2004-02-20 | 2006-12-05 | 노파르티스 아게 | 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제 |
| EP1778196A4 (en) * | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| EP2007369A4 (en) * | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| US20100092554A1 (en) * | 2007-04-24 | 2010-04-15 | Boehringer Ingelheim International Gmbh | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| MX2010013393A (es) * | 2008-06-06 | 2011-06-21 | Pharma Two B Ltd | Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson. |
| CN102186350A (zh) * | 2008-08-19 | 2011-09-14 | 诺普神经科学股份有限公司 | 使用(r)-普拉克索的组合物与方法 |
| RU2734632C2 (ru) * | 2010-02-03 | 2020-10-21 | Фарма Ту Б Лтд. | Составы разагилина с пролонгированным высвобождением и их применение |
-
2013
- 2013-01-10 ES ES13736198.6T patent/ES2655676T3/es active Active
- 2013-01-10 US US14/372,067 patent/US20150079187A1/en not_active Abandoned
- 2013-01-10 IN IN1568MUN2014 patent/IN2014MN01568A/en unknown
- 2013-01-10 HU HUE13736198A patent/HUE038029T2/hu unknown
- 2013-01-10 KR KR1020147022416A patent/KR102276896B1/ko active Active
- 2013-01-10 PT PT137361986T patent/PT2802319T/pt unknown
- 2013-01-10 CA CA2860952A patent/CA2860952C/en active Active
- 2013-01-10 WO PCT/IL2013/050025 patent/WO2013105092A1/en not_active Ceased
- 2013-01-10 NO NO13736198A patent/NO2802319T3/no unknown
- 2013-01-10 MX MX2014008537A patent/MX360409B/es active IP Right Grant
- 2013-01-10 AU AU2013208653A patent/AU2013208653B2/en active Active
- 2013-01-10 KR KR1020207002459A patent/KR20200013791A/ko not_active Ceased
- 2013-01-10 DK DK13736198.6T patent/DK2802319T3/da active
- 2013-01-10 JP JP2014551726A patent/JP6243351B2/ja active Active
- 2013-01-10 RU RU2014132940A patent/RU2642962C9/ru active
- 2013-01-10 EP EP13736198.6A patent/EP2802319B1/en active Active
- 2013-01-10 LT LTEP13736198.6T patent/LT2802319T/lt unknown
- 2013-01-10 RS RS20180050A patent/RS56742B1/sr unknown
- 2013-01-10 PL PL13736198T patent/PL2802319T3/pl unknown
- 2013-01-10 CN CN201380014052.8A patent/CN104168896B/zh active Active
- 2013-09-30 NO NO13840443A patent/NO2901008T3/no unknown
-
2014
- 2014-07-09 IL IL233572A patent/IL233572B/en active IP Right Grant
-
2018
- 2018-01-17 CY CY20181100061T patent/CY1119793T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508411A5 (enExample) | ||
| EA201071054A1 (ru) | Твердый препарат, растворяющийся во рту | |
| EA201591821A1 (ru) | Защищенные от несанкционированного использования фармацевтические составы | |
| WO2012131463A3 (en) | Controlled release pharmaceutical dosage forms | |
| WO2013009142A3 (en) | Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same | |
| MX2016014320A (es) | Composiciones de suspension de liberacion prolongada. | |
| CL2013002504A1 (es) | Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion | |
| JP2015147774A5 (enExample) | ||
| MX2015000114A (es) | Composiciones farmaceuticas disuasivas de abuso de liberacion prolongada. | |
| WO2009059701A3 (de) | Retardtabletten mit hydromorphon | |
| WO2014059269A3 (en) | Multilayer compositions, coated devices and use thereof | |
| JP2014218522A5 (enExample) | ||
| HK1203815A1 (en) | Pharmaceutical compositions and methods for their preparation | |
| WO2011140446A3 (en) | Pharmaceutical formulations | |
| MX375936B (es) | Composiciones farmaceuticas mejoradas de pimobendan. | |
| BR112015030140A2 (pt) | forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral | |
| WO2016205738A3 (en) | Delivery systems for controlled drug release | |
| CR20150077A (es) | Composición farmacéutica oral en forma de microesferas y proceso de elaboración | |
| WO2016142708A3 (en) | Pharmaceutical composition | |
| AR092356A1 (es) | Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion | |
| WO2011119288A3 (en) | Multilayer melt-extruded film | |
| WO2014181195A3 (en) | Antiemetic extended release solid dosage forms | |
| SI2612681T1 (sl) | Obložno sredstvo za farmacevtsko trdno obliko, farmacevtska filmska formulacija in obložena farmacevtska trdna oblika | |
| WO2012111996A3 (ko) | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 | |
| MY184693A (en) | Bilayer hydrocolloid films containing therapeutic agents |